Tom Langenaeken: Targeting Factor XI in Mechanical Heart Valve Thrombosis
Tom Langenaeken, Resident Cardiac Surgery at Catharina Ziekenhuis, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Blood Vessels, Thrombosis & Haemostasis, adding:
“Our paper on Factor XI inhibition with gruticibart (AB023) for mechanical heart valve thrombosis is now published in Blood Vessels, Thrombosis & Haemostasis.
In a porcine pulmonary valve model, gruticibart achieved 100% valve patency without bleeding events at three months despite IV administration only once every 2 weeks.
A result we believe makes a compelling case for FXI as the target antithrombotic strategy in mechanical valve recipients.
This pilot study is the foundation for a larger follow-up series, which we are pleased to pursue with support from the Foundation for Cardiac Surgery.”
Title: Factor XI inhibition with gruticibart prevents mechanical valve thrombosis in a porcine pulmonary model
Authors: Tom Langenaeken, Lennart Vanglabeke, Manon Van Hecke, Pieter De Meester, Tom Verbelen, Peter Verbrugghe, Filip Rega, Christina U Lorentz, Erik I Tucker, Bart Meuris

Stay updated on all scientific advances with Hemostasis Today.
-
Jun 13, 2026, 15:39Ritu Verma: Recognizing Deep Vein Thrombosis Before Complications Arise
-
Jun 13, 2026, 15:09Akshat Jain: Does Mitapivat Translate to Clinical Benefit in SCD?
-
Jun 13, 2026, 14:58Olga Benítez Hidalgo: New Evidence on Marstacimab in Hemophilia Care
-
Jun 13, 2026, 14:52Sophie Georgin-Lavialle: First ERN-RITA Recommendations on USAID
-
Jun 13, 2026, 14:48Andrew Jackson: Personalized Approaches to Catheter-Related Thrombosis Prevention
-
Jun 13, 2026, 14:45Ghazaleh Bankefors: Reconnecting Across Borders and Decades at EHA 2026
-
Jun 13, 2026, 14:36Heghine Khachatryan: Pregnancy, Thrombosis, and Aspirin – Who Really Needs Prophylaxis?
-
Jun 13, 2026, 14:24Thomas Stauch: ITP Therapeutics Enter a New Era of Targeted Treatment
-
Jun 13, 2026, 14:07Long-Term Outcomes and Future Directions in Hemophilia Gene Therapy: Insights from EHA 2026